Ribomic Inc
TSE:4591
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Golab SA
WSE:GOL
|
PL |
Ribomic Inc
Intangible Assets
Ribomic Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ribomic Inc
TSE:4591
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Intangible Assets
¥43.9m
|
CAGR 3-Years
178%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Intangible Assets
¥12.3B
|
CAGR 3-Years
62%
|
CAGR 5-Years
48%
|
CAGR 10-Years
46%
|
|
|
PeptiDream Inc
TSE:4587
|
Intangible Assets
¥2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
91%
|
CAGR 10-Years
79%
|
|
|
Takara Bio Inc
TSE:4974
|
Intangible Assets
¥11.9B
|
CAGR 3-Years
64%
|
CAGR 5-Years
29%
|
CAGR 10-Years
27%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ribomic Inc
Glance View
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 25 full-time employees. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
